NeuroSense Therapeutics has reached a significant milestone in its PARADIGM Phase 2b ALS clinical trial with the completion of 18-month dosing, marked by the Last Patient Last Visit. The company is now preparing to report comprehensive top-line clinical results from the full study in early December 2024.The trial evaluates PrimeC as a potential treatment for ALS (Amyotrophic Lateral Sclerosis). This development represents a crucial step in assessing the safety and efficacy of PrimeC in targeting ALS, though outcomes remain subject to final analysis and regulatory review by the FDA and Health Canada.

NeuroSense Therapeutics has reached a significant milestone in its PARADIGM Phase 2b ALS clinical trial with the completion of 18-month dosing, marked by the Last Patient Last Visit. The company is now preparing to report comprehensive top-line clinical results from the full study in early December 2024.The trial evaluates PrimeC as a potential treatment for ALS (Amyotrophic Lateral Sclerosis). This development represents a crucial step in assessing the safety and efficacy of PrimeC in targeting ALS, though outcomes remain subject to final analysis and regulatory review by the FDA and Health Canada.